2012•Annals of the Rheumatic DiseasesRequires access

AB0482 The cytotoxic effects of certolizumab pegol and golimumab mediated by transmembrane tumor necrosis factor α

Naoyuki Ueda, Hiroshi Tsukamoto, Hiroki Mitoma, Masahiro Ayano, Akira Tanaka, Satoshi Ohta, Yasushi Inoue, Yojirou Arinobu, Hiroaki Niiro, Koichi Akashi, Takahiko Horiuchi

Open publisher page 3 citations

Abstract

This record does not include an abstract. Use the full-text link above if available.

About this research paper

What this paper is about

An abstract is not available in the OpenAlex record for this paper.

Why it matters

OpenAlex reports 3 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Key concepts: Certolizumab pegol, Golimumab, Adalimumab, Antibody-dependent cell-mediated cytotoxicity, Infliximab, Medicine, Tumor necrosis factor alpha, Pharmacology

Back to paper search Browse research topics Original source

AB0482 The cytotoxic effects of certolizumab pegol and golimumab mediated by transmembrane tumor necrosis factor α — Research Paper | ScholarLens